Primary sources and immunological prerequisites for sST2 secretion in humans

Cardiovascular Research

Volumn 87, Issue 4, 2010, Pages 769-777

  Mildner, Michael ^a   Storka, Angela ^b   Lichtenauer, Michael ^b   Mlitz, Veronika ^a   Ghannadan, Minoo ^a   Hoetzenecker, Konrad ^b   Nickl, Stefanie ^b   Dome, Balazs ^c   Tschachler, Erwin ^a,d   Ankersmit, Hendrik Jan ^b  

^a Universitatsklinik fur Dermatologie   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^d Centre de Recherches et d'Investigations Epidermiques et Sensorielles CERIES   (France)

Author keywords

Alveolar epithelial cells; Cardiac myocytes; Cell culture; Inflammation; Soluble growth stimulation gene 2

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BRAIN TISSUE; CELL TYPE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE EXPRESSION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INFLAMMATION; LUNG ALVEOLUS EPITHELIUM; MALE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLUBLE GROWTH STIMULATION GENE 2;

ADAPTIVE IMMUNITY; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MYOCYTES, CARDIAC; NF-KAPPA B; PULMONARY ALVEOLI; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955908581     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq104     Document Type: Article

References (51)

1. Klemenz R, Hoffmann S, Werenskiold AK. Serum-and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen. Proc Natl Acad Sci USA 1989;86:5708-5712.
2. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 1989;258:301-304.
3. Tominaga S, Yokota T, Yanagisawa K, Tsukamoto T, Takagi T, Tetsuka T. Nucleotide sequence of a complementary DNA for human ST2. Biochim Biophys Acta 1992;1171: 215-218.
4. Bergers G, Reikerstorfer A, Braselmann S, Graninger P, Busslinger M. Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor. EMBO J 1994;13:1176-1188.
5. Tominaga S, Jenkins NA, Gilbert DJ, Copeland NG, Tetsuka T. Molecular cloning of the murine ST2 gene. Characterization and chromosomal mapping. Biochim Biophys Acta 1991;1090:1-8.
6. Dale M, Nicklin MJ. Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1, IL1RL2 (IL-1Rrp2), IL1RL1 (T1/ST2), and IL18R1 (IL-1Rrp) on human chromosome 2q. Genomics 1999;57:177-179.
7. Iwahana H, Yanagisawa K, Ito-Kosaka A, Kuroiwa K, Tago K, Komatsu N et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 1999;264: 397-406.
8. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479-490.
9. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007;282:26369-26380.
10. Sweet MJ, Leung BP, Kang D, Sogaard M, Schulz K, Trajkovic V et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001;166:6633-6639.
11. Takezako N, Hayakawa M, Hayakawa H, Aoki S, Yanagisawa K, Endo H et al. ST2 suppresses IL-6 production via the inhibition of IkappaB degradation induced by the LPS signal in THP-1 cells. Biochem Biophys Res Commun 2006;341:425-432.
12. Yanagisawa K, Naito Y, Kuroiwa K, Arai T, Furukawa Y, Tomizuka H et al. The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells. J Biochem 1997;121:95-103.
13. Yanagisawa K, Takagi T, Tsukamoto T, Tetsuka T, Tominaga S. Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett 1993;318:83-87.
14. Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, O'Neill LA et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004;5:373-379.
15. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005;5:446-458.
16. Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem 2009;284:19420-19426.
17. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA 2009;106:9021-9026.
18. Hacker S, Lambers C, Pollreisz A, Hoetzenecker K, Lichtenauer M, Mangold A et al. Increased soluble serum markers caspase-cleaved cytokeratin-18, histones, and ST2 indicate apoptotic turnover and chronic immune response in COPD. J Clin Lab Anal 2009;23:372-379.
19. Untersmayr E, Bakos N, Schöll I, Kundi M, Roth-Walter F, Szalai K et al. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB J 2005;19:656-658.
20. Kanda M, Ohto-Ozaki H, Kuroiwa K, Tominaga S, Watanabe E, Iwahana H. Elevation of ST2 protein levels in cerebrospinal fluid following subarachnoid hemorrhage. Acta Neurol Scand 2006;113:327-333.
21. Brunner M, Krenn C, Roth G, Moser B, Dworschak M, Jensen-Jarolim E et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 2004;30:1468-1473.
22. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem Biophys Res Commun 2002;299:18-24.
23. Becerra A, Warke RV, de BN, Rothman AL, Bosch I. Elevated levels of soluble ST2 protein in dengue virus infected patients. Cytokine 2008;41:114-120.
24. Szerafin T, Brunner M, Horváth A, Szentgyörgyi L, Moser B, Boltz-Nitulescu G et al. Soluble ST2 protein in cardiac surgery: a possible negative feedback loop to prevent uncontrolled inflammatory reactions. Clin Lab 2005;51:657-663.
25. Szerafin T, Niederpold T, Mangold A, Hoetzenecker K, Hacker S, Roth G et al. Secretion of soluble ST2\possible explanation for systemic immunosuppression after heart surgery. Thorac Cardiovasc Surg 2009;57:25-29.
26. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohor-mone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008;117:1936-1944.
27. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107: 721-726.
28. Brown AM, Wu AH, Clopton P, Robey JL, Hollander JE. ST2 in emergency department chest pain patients with potential acute coronary syndromes. Ann Emerg Med 2007;50:153-158.
29. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004;109:2186-2190.
30. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106: 2961-2966.
31. Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, De Wiest B et al. Non-myocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 2008;52:2166-2174.
32. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
33. Kadl A, Huber J, Gruber F, Bochkov VN, Binder BR, Leitinger N. Analysis of inflammatory gene induction by oxidized phospholipids in vivo by quantitative real-time RT-PCR in comparison with effects of LPS. Vascul Pharmacol 2002;38:219-227.
34. Natarajan K, Singh S, Burke TR Jr, Grunberger D, Aggarwal BB. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci USA 1996;93:9090-9095.
35. Jung WK, Lee DY, Choi YH, Yea SS, Choi I, Park SG et al. Caffeic acid phenethyl ester attenuates allergic airway inflammation and hyperresponsiveness in murine model of ovalbumin-induced asthma. Life Sci 2008;82:797-805.
36. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995;92:1479-1486.
37. Sharma R, Anker SD. Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol 2002;85:161-171.
38. Spanier T, Tector K, Schwartz G, Chen J, Oz M, Beck J et al. Endotoxin in pooled peri-cardial blood contributes to the systemic inflammatory response during cardiac surgery. Perfusion 2000;15:427-431.
39. Miki C, McMaster P, Mayer AD, Iriyama K, Suzuki H, Buckels JA. Factors predicting perioperative cytokine response in patients undergoing liver transplantation. Crit Care Med 2000;28:351-354.
40. Jankowska EA, von Haehling S, Czarny A, Zaczynska E, Kus A, Anker SD et al. Activation of the NF-kappaB system in peripheral blood leukocytes from patients with chronic heart failure. Eur J Heart Fail 2005;7:984-990.
41. Muller JM, Ziegler-Heitbrock HW, Baeuerle PA. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology 1993;187:233-256.
42. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1: 135-145.
43. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007;449:819-826.
44. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-376.
45. Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 2003;3:169-176.
46. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004;16:3-9.
47. Prabhakar U, Conway TM, Murdock P, Mooney JL, Clark S, Hedge P et al. Correlation of protein and gene expression profiles of inflammatory proteins after endotoxin challenge in human subjects. DNA Cell Biol 2005;24:410-431.
48. Schmidt WM, Spiel AO, Jilma B, Wolzt M, Muller M. In vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics 2008;18:109-120.
49. van't Veer C, van den Pangaart PS, van Zoelen MA, de Kruif M, Birjmohun RS, Stroes ES et al. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol 2007;179:7110-7120.
50. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001;13:114-119.
51. Espinassous Q, Garcia-de-Paco E, Garcia-Verdugo I, Synguelakis M, von Aulock S, Sallenave JM et al. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol 2009;183:1446-1455.